These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

794 related articles for article (PubMed ID: 496103)

  • 1. Risk factors for doxorubicin-induced congestive heart failure.
    Von Hoff DD; Layard MW; Basa P; Davis HL; Von Hoff AL; Rozencweig M; Muggia FM
    Ann Intern Med; 1979 Nov; 91(5):710-7. PubMed ID: 496103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules.
    Berrak SG; Ewer MS; Jaffe N; Pearson P; Ried H; Zietz HA; Benjamin RS
    Oncol Rep; 2001; 8(3):611-4. PubMed ID: 11295089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group.
    Green DM; Grigoriev YA; Nan B; Takashima JR; Norkool PA; D'Angio GJ; Breslow NE
    J Clin Oncol; 2001 Apr; 19(7):1926-34. PubMed ID: 11283124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience.
    Ibrahim NK; Hortobagyi GN; Ewer M; Ali MK; Asmar L; Theriault RL; Fraschini G; Frye DK; Buzdar AU
    Cancer Chemother Pharmacol; 1999; 43(6):471-8. PubMed ID: 10321507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
    Schwartz RG; McKenzie WB; Alexander J; Sager P; D'Souza A; Manatunga A; Schwartz PE; Berger HJ; Setaro J; Surkin L
    Am J Med; 1987 Jun; 82(6):1109-18. PubMed ID: 3605130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QRS voltage change with adriamycin administration.
    Minow RA; Benjamin RS; Lee ET; Gottlieb JA
    Cancer Treat Rep; 1978 Jun; 62(6):931-4. PubMed ID: 667870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adriamycin cardiomyopathy--risk factors.
    Minow RA; Benjamin RS; Lee ET; Gottlieb JA
    Cancer; 1977 Apr; 39(4):1397-402. PubMed ID: 856438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial studies of cardiac function in patients receiving adriamycin.
    Henderson IC; Sloss LJ; Jaffe N; Blum RH; Frei E
    Cancer Treat Rep; 1978 Jun; 62(6):923-9. PubMed ID: 667869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity.
    Chlebowski RT; Paroly WS; Pugh RP; Hueser J; Jacobs EM; Pajak TF; Bateman JR
    Cancer Treat Rep; 1980 Jan; 64(1):47-51. PubMed ID: 7379058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radionuclide ventriculography for evaluation and prevention of doxorubicin cardiotoxicity.
    Steinberg JS; Wasserman AG
    Clin Ther; 1985; 7(6):660-7. PubMed ID: 3907840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
    Skubitz KM; Blaes AH; Konety SH; Francis GS
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.
    Swain SM; Whaley FS; Ewer MS
    Cancer; 2003 Jun; 97(11):2869-79. PubMed ID: 12767102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysing the risk factors of doxorubicin-associated heart failure by a retrospective study of integrated, nation-wide databases].
    Fogarassy G; Fogarassyné Vathy Á; Kováts T; Hornyák L; Kenessey I; Veress G; Polgár C; Forster T
    Orv Hetil; 2020 Jun; 161(26):1094-1102. PubMed ID: 32541088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.
    Feijen EA; Leisenring WM; Stratton KL; Ness KK; van der Pal HJ; Caron HN; Armstrong GT; Green DM; Hudson MM; Oeffinger KC; Robison LL; Stovall M; Kremer LC; Chow EJ
    J Clin Oncol; 2015 Nov; 33(32):3774-80. PubMed ID: 26304888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversible doxorubicin-induced congestive heart failure.
    Cohen M; Kronzon I; Lebowitz A
    Arch Intern Med; 1982 Aug; 142(8):1570-1. PubMed ID: 7103641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthracycline cardiomyopathy in children: report of two cases.
    Mosijczuk AD; Ruymann FB; Mease AD; Bernier RD
    Cancer; 1979 Nov; 44(5):1582-7. PubMed ID: 291472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects.
    Bauch M; Ester A; Kimura B; Victorica BE; Kedar A; Phillips MI
    Cancer; 1992 Mar; 69(6):1492-7. PubMed ID: 1531780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adriamycin (doxorubicin) cardiotoxicity: a review.
    Chlebowski RT
    West J Med; 1979 Nov; 131(5):364-8. PubMed ID: 394479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.